Dr. Epstein reports zero capsular contracture after 210 Preservé breast augmentations

Epstein Plastic Surgery says a one-year review of 210 consecutive Preservé breast augmentation procedures found zero Grade III/IV capsular contracture, infections, implant ruptures, or lost nipple sensation. The results matter because they add full-case-series data to a newer technique that has been adopted by a small group of surgeons.

Why it matters: - The one-year outcomes add a full case-series checkpoint to the Preservé breast augmentation technique after 210 consecutive procedures. - Zero Grade III/IV capsular contracture across 420 breasts is the headline result. - The data may influence how surgeons evaluate newer implant techniques and patient recovery goals.

What happened: - Dr. Mark Epstein of Epstein Plastic Surgery completed one year of Preservé breast augmentation outcomes tracking at his Hauppauge, New York practice. - The first Preservé procedure at the practice took place on September 10, 2025. - The review covers 210 procedures and 420 breasts. - The twelve-month series recorded zero Grade III/IV capsular contracture, zero infections, zero implant ruptures, and zero cases of lost nipple sensation. - Two reoperations for complications were recorded, for a 0.4% rate. - Fifteen of the 210 procedures were performed wide awake.

The details: - Dr. Epstein is one of 12 surgeons nationally trained to teach the Preservé technique to other plastic surgeons. - Dr. Epstein served as a paid investigator in the Motiva U.S. FDA clinical trial that led to the implant’s approval in September 2024. - Dr. Epstein has personally trained 67 surgeons in the technique to date. - Dr. Epstein said, “I have been doing this for over thirty years, and I have never had a technique change my outcomes this fast. The data after one year makes the case better than I can.” - Dr. Epstein was named to Newsweek’s list of America’s Best Plastic Surgeons 2026 in five categories: breast augmentation, rhinoplasty, eye lift, liposuction and tummy tuck. - Epstein Plastic Surgery says the Preservé technique is offered alongside multiple anesthesia options, including a wide awake approach for appropriate candidates. - Full case mix and outcomes data are available at the practice’s published report. - Epstein Plastic Surgery describes itself as a Hauppauge practice focused exclusively on cosmetic surgery with an on-site accredited surgical facility and an on-site medspa, Oceane Medical Aesthetics and Wellness. - Epstein Plastic Surgery says both facilities are accredited by QUAD A. - Dr. Mark Epstein has practiced plastic surgery on Long Island for more than 30 years.

Between the lines: - The results come from a single surgeon’s consecutive series, so they are more specific than a marketing claim but narrower than a multi-center study. - The absence of major complications in the series is notable, but the data still reflect one practice and one technique under one surgeon’s hands. - Dr. Epstein’s training role and investment ties to Establishment Labs are relevant context for readers evaluating the technique and the reported outcomes. - Dr. Epstein is a paid investigator in the Motiva U.S. FDA clinical trial and is compensated by Establishment Labs to train surgeons on the Preservé technique. - Dr. Epstein owns stock in Establishment Labs.

What's next: - Epstein Plastic Surgery is expected to continue tracking Preservé outcomes beyond the first year. - Dr. Epstein’s role as a trainer suggests wider surgeon adoption may continue as more physicians learn the technique. - Additional longer-term data will be important to see whether the one-year results hold up over time.

The bottom line: - Epstein Plastic Surgery is using a full 12-month, 210-case series to argue that Preservé breast augmentation can deliver strong early safety results in experienced hands.